accidentally stopping paroxetine treatment, he became anxious, agitated, irritable, confused, showing severe gait ataxia and bilateral motor weakness. He was admitted to a tertiary care hospital and investigated for vertebrobasilar insufficiency. Magnetic resonance imaging (MRI) showed extensive hyperintense T2 signal foci within cerebral white matter, as well as in the left pons, suggesting nonspecific smallvessel ischemic disease. Magnetic resonance angiography revealed mild occlusion or hypoplasia of the right A1 segment of the anterior cerebral artery.
His blood pressure was elevated to 150/100 mm Hg. The symptoms of agitation, anxiety, insomnia, gait ataxia, and bilateral motor weakness were cleared 24 to 48 hours after paroxetine treatment was reinstituted at the previous dosage. Four months later, his cardiologist abruptly discontinued paroxetine treatment, owing to potential anticholinergic and cardiac side effects. The patient was readmitted to the same tertiary hospital with anxiety, agitation, confusion, gait ataxia, and bilateral motor weakness. A repeat MRI showed no progression in cortical white matter and pontine ischemic changes. The discontinuation symptoms, ataxia, and motor weakness resolved within 48 hours after the reintroduction of paroxetine treatment at the previous dosage. Because vertebrobasilar insufficiency lasted for more than 24 hours and brain parenchyma might be irreversibly altered owing to prolonged ischemic attack, the diagnosis of ministroke involving vertebrobasilar territory was considered.
Discussion
The emergence of anxiety, agitation, and insomnia within 24 to 48 hours of abrupt discontinuation of paroxetine maintenance treatment and the resolution of these symptoms after reinstating the previous paroxetine treatment concurs with the diagnosis of SSRI discontinuation syndrome (1). This patient suffered minor strokes involving vertebrobasilar territory, as determined by neurological investigations and stroke neurologists. Hence, in this patient manifested ataxia and motor weakness during a discontinuation phase may indicate minor stroke involving vertebrobasilar territory, rather than the physical symptoms of discontinuation syndrome. Moreover, in the presence of cerebrovascular disease, ataxia and motor weakness could not be considered as discontinuation symptoms. Further, since there was a temporal relation between the onset of minor strokes and the discontinuation of paroxetine treatment on both occasions, it is unlikely that these minor strokes were just coincidental manifestations of the underlying cerebrovascular disease. The possibilities of SSRI treatmentassociated cerebrovascular bleeding and vasoconstrictive stroke may be irrelevant: this patient developed minor strokes after the discontinuation of paroxetine maintenance treatment (3, 4) .
Paroxetine has been frequently implicated in SSRI discontinuation syndrome, owing to its short half-life (5) . Cholinergic overdrive activating monoaminergic systems, coupled with hyposerotonergic state after the discontinuation of paroxetine treatment, may be responsible for discontinuation symptoms (6, 7) . Elevated blood pressure and a possible decrease in cerebrovascular reserve because of activation of catecholamines and resulting anxiety during discontinuation syndrome might have contributed to minor strokes in this patient (8, 9) . Given the possibility of cerebrovascular events as consequences to anxiety and agitation during discontinuation syndrome, it is imperative to minimize discontinuation symptoms by slowly tapering SSRI treatment in elderly subjects with cerebrovascular disease.
Quetiapine Reduces Flashbacks in Chronic Posttraumatic Stress Disorder
Dear Editor:
Chronic posttraumatic stress disorder (PTSD) is a severe and resistant disorder involving complex symptom clusters and comorbid psychiatric diagnoses that often respond poorly to antidepressants (1-3). Combination therapy is almost always necessary, with antidepressants associated with mood stabilizers and, more recently, with atypical antipsychotics, for which there are preliminary efficacy data (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) .
We treated 5 patients with chronic PTSD: 3 men with PTSD after Bosnia missions some 10 years ago and 2 women, 1 of whom was physically attacked by her husband during their divorce 2 years earlier and 1 of whom was raped by a stranger.
All 5 patients had already been treated with combination therapy using selective serotonin reuptake inhibitors (SSRIs) or venlafaxine plus gabapentin, and 1 patient had been prescribed lamotrigine. This last patient was the only one who presented with psychotic symptoms. All patients had seen an improvement in anxiety, aggressivity, and sleep but were still haunted by flashbacks.
Quetiapine was gradually added to their regimen, up to 150 mg or 200 mg daily, and all 4 patients noted a dramatic reduction in their diurnal flashbacks, without excessive sedation. The flashbacks, which occurred many times daily, became much less frequent, happening only a few times (or fewer) weekly. In all 5 patients, we were able to gradually reduce gabapentin, and in 3 of the 5 patients, we stopped it completely.
Chronic PTSD is now commonly treated with combination therapy. Atypical antipsychotics seem very popular as adjunctive agents in this disabling disorder (4) . Still, there are few controlled data to support this practice.
In several case reports, risperidone has shown efficacy in treating flashbacks and other intrusive symptoms that relate to traumatic events, as well as in treating irritable aggression (5) (6) (7) (8) . One controlled study with risperidone targeted psychotic features in combat veterans with chronic PTSD. In this trial, positive and negative psychotic symptoms improved, compared with the placebo group, but core PTSD symptoms measured by total Clinician Administered PTSD Scale (CAPS) score did not differ from those in the placebo group (9) .
Another small controlled trial with olanzapine (15 civilians randomized to monotherapy or placebo), did not differentiate the active drug from the placebo, although an open-label study suggested benefits for olanzapine in 48 veterans with chronic PTSD (10, 11) . In this last study, however, one-third of subjects failed to complete the trial, largely because of adverse events or noncompliance (11) .
A case report found clozapine useful in a treatment-refractory patient with combat-associated PTSD and psychosis (12) .
With respect to using quetiapine as an adjunctive treatment, Hamner and others completed an open-label trial in 20 refractory patients with PTSD, and the results are encouraging. The average dosage of quetiapine was 100 mg daily, with a range of 25 mg to 300 mg daily. Patients experienced improved sleep and a reduction in the frequency and intensity of nightmares. The total CAPS rating and the symptom clusters were also significantly improved by quetiapine (13) .
In our experience, quetiapine adjunctive treatment has reduced flashbacks in 5 chronically affected PTSD patientsflashbacks being one of the core and most painful symptoms in PTSD.
Use of quetiapine as adjunctive treatment and monotherapy for PTSD needs assessment in well-designed clinical trials with larger samples, because it may represent an interesting treatment option in PTSD.
Behaviour Therapy for Dizziness?
A woman in her mid-30s presented with recurrent, unexplained dizziness. Two years prior to presentation, she had a 3-to 4-hour period of dizziness, nausea, and vomiting. She saw her family doctor and was told that she had a viral illness, but since then, she has become fearful of further episodes of dizziness. When she felt dizzy, she immobilized her head and neck for several hours until the feeling of dizziness disappeared. She saw numerous physicians who performed many investigations to rule out medical conditions. She was quite distressed about these episodes and had significant anticipatory anxiety with respect to the dizziness. She had decreased functioning at her work because of dizziness. However, she did not meet criteria for panic attacks. Otherwise, she was healthy and had no other psychiatric or medical comorbidity. She did not take any medications. There was no family history of anxiety problems.
The diagnosis of limited-symptom panic disorder was the best explanation for this presentation. Although pharmacotherapy (that is, a serotonin reuptake inhibitor [SRI]) was considered, this treatment modality was avoided, owing to the sensitivity of patients with panic disorder to side effects of antidepressants and to this woman's limited-symptom panic attacks.
She was treated with 4 individual sessions, using exposure and response prevention. In the first 2 sessions, it was explained to the patient that she had developed fear of the dizziness sensation through classic conditioning. The more she tried to avoid the sensation, the more sensitive she had become to any head movement that resulted in slight dizziness sensations. She was asked to gradually expose herself to the dizziness sensation by spinning around for 30 to 60 seconds daily. She responded well to the systematic desensitization, with no further episodes of dizziness. She was followed for 6 months and maintained her improvement.
Dizziness that is unrelated to a medical condition is a common problem in the population (1-3) and is associated with significant disability and high rates of medical services use (4, 5) . Recent studies have demonstrated that a significant proportion of persons with unexplained dizziness have an underlying anxiety disorder diagnosis (6, 7) . Recognition and treatment of this problem is likely to reduce disability and costs to society. A recent open-label trial confirmed that most people with psychogenic dizziness respond to treatment with an SRI antidepressant (8) . Of the sample in this study, however, 25% stopped the antidepressant because of adverse effects (8) . With respect to nonpharmacologic strategies, data support behaviour therapy and vestibular rehabilitation as similar and
